← All diseases

Disease Atlas / Disease detail

Immunodeficiency-centromeric instability-facial anomalies syndrome

An explanation of the features, diagnosis, management, and research questions of a rare genetic disorder that can involve immunodeficiency and chromosomal instability.

immunodeficiency-centromeric instability-facial anomalies syndrome

MONDO:0000133Public QA completeSource-bound · 2

Disease at a glance

Start with the essentials, then explore the patient and research views.

Public revision · a6e02f8b4787

Disease category
Immunodeficiency-centromeric instability-facial anomalies syndrome is a rare genetic disorder in which immunodeficiency, centromeric chromosomal instability, and characteristic facial features can occur together.
Core mechanism
The disorder is usually inherited in an autosomal recessive pattern, and DNMT3B-related abnormalities are a major known cause.
Main causes and associated factors
Changes in DNA methylation and chromosomal stability can affect the immune system and the development of multiple tissues.
Typical manifestations
Typical clinical features may include recurrent bacterial or viral infections, characteristic facial features, growth delay, developmental problems, and skeletal abnormalities.
Individual variation
Because autosomal recessive inheritance is common, family history and the parents' carrier status can help assess risk, although symptom severity may vary even within the same family.
Diagnosis
Symptoms often begin in infancy or childhood, but their onset and natural history vary; recurrent infections can lead to chronic lung damage or impaired growth.
Management
Diagnosis combines clinical features, immunoglobulin and lymphocyte assessment, tests for chromosomal instability, and, when needed, molecular genetic testing that includes DNMT3B.
Treatment and research status
The diagnosis cannot be confirmed from infection frequency or facial features alone, and the clinical significance of genetic variants and test results should be interpreted with specialist genetic and immunology counseling.
Reading the evidence
Management focuses on preventing infections and treating them promptly, with multidisciplinary monitoring of immune status, lung function, growth and development, and blood abnormalities.
Key caution
Treatment mainly consists of supportive measures tailored to each person's immune defects and complications, and no single curative treatment has been established for every patient.

For patients and families

A structured guide for understanding the disease and preparing for clinical conversations.

At a glance

Immunodeficiency-centromeric instability-facial anomalies syndrome is a rare genetic disorder in which immunodeficiency, centromeric chromosomal instability, and characteristic facial features can occur together.

Typical clinical features may include recurrent bacterial or viral infections, characteristic facial features, growth delay, developmental problems, and skeletal abnormalities.

How the disorder works

The disorder is usually inherited in an autosomal recessive pattern, and DNMT3B-related abnormalities are a major known cause.

Changes in DNA methylation and chromosomal stability can affect the immune system and the development of multiple tissues.

How it varies from person to person

Because autosomal recessive inheritance is common, family history and the parents' carrier status can help assess risk, although symptom severity may vary even within the same family.

Overall approach to diagnosis and management

Symptoms often begin in infancy or childhood, but their onset and natural history vary; recurrent infections can lead to chronic lung damage or impaired growth.

Diagnosis combines clinical features, immunoglobulin and lymphocyte assessment, tests for chromosomal instability, and, when needed, molecular genetic testing that includes DNMT3B.

Current state of treatment

The diagnosis cannot be confirmed from infection frequency or facial features alone, and the clinical significance of genetic variants and test results should be interpreted with specialist genetic and immunology counseling.

Management focuses on preventing infections and treating them promptly, with multidisciplinary monitoring of immune status, lung function, growth and development, and blood abnormalities.

Treatment mainly consists of supportive measures tailored to each person's immune defects and complications, and no single curative treatment has been established for every patient.

How to read clinical trials

Follow-up should track infection history, immune tests, lung and blood status, and growth and development over time, while evaluating test results together with treatment response.

Points to discuss during a clinical visit

During clinical care, it is important to review the types and frequency of recurrent infections, vaccination and antibiotic history, family history, changes in growth and development, the meaning of test results, and the long-term follow-up plan.

Medical information

This material is for educational purposes and is not a guide for individual diagnosis or treatment. Personal symptoms and treatment should be discussed with a healthcare professional.

Evidence and sources

A trial registry status does not establish efficacy or regulatory approval.